<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01357720</url>
  </required_header>
  <id_info>
    <org_study_id>QVX-V-A001</org_study_id>
    <nct_id>NCT01357720</nct_id>
  </id_info>
  <brief_title>Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood Vaccination</brief_title>
  <official_title>A Phase IV, Single-blind, Randomized, Controlled, Monocentric Study to Assess the Interchangeability of Quinvaxem (DTwP-HepB-Hib) as the 2nd and 3rd Dose After Initial Vaccination With Tritanrix HB+Hib (DTwP-HepB/Hib) With Respect to Safety and Immunogenicity in Healthy Infants at 6, 10 and 14 Weeks of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Crucell Holland BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Crucell Holland BV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to show that vaccination with 1 dose of Tritanrix HB+Hib followed by
      Quinvaxem vaccine as the 2nd and 3rd dose is not inferior to vaccination with Quinvaxem for
      all 3 doses, with respect to protection against all antibodies (anti-hepatitis B surface
      antibodies, anti-polyribosyl ribitol phosphate (PRP), anti-diphtheria, anti-tetanus and
      anti-Bordetella pertussis) 1 month after completion of the 6-10-14 week vaccination course.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroprotection Rate: Anti-PRP Antibodies</measure>
    <time_frame>1 month after the third vaccination</time_frame>
    <description>Percentage of subjects with an anti-PRP titer ≥0.15 µg/mL (i.e. seroprotection rate)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroprotection Rate: Anti-hepatitis B Surface Antibodies</measure>
    <time_frame>1 month after the third vaccination</time_frame>
    <description>Percentage of subjects with an anti-hepatitis B surface antibody titer ≥10 IU/L (i.e. seroprotection rate)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroprotection Rate: Anti-diphtheria Toxoid Antibodies</measure>
    <time_frame>1 month after the third vaccination</time_frame>
    <description>Percentage of subjects with antibody levels against diphtheria toxoid ≥0.1 IU/mL (i.e. seroprotection rate)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroprotection Rate: Anti-tetanus Toxoid Antibodies</measure>
    <time_frame>1 month after the third vaccination</time_frame>
    <description>Percentage of subjects with antibody levels against tetanus toxoid ≥0.1 IU/mL (i.e. seroprotection rate)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroprotection Rate: Anti-B. Pertussis Antibodies</measure>
    <time_frame>1 month after the third vaccination</time_frame>
    <description>Percentage of subjects with an anti-B. pertussis antibody titer ≥20 EU/mL or a 4-fold increase over baseline (i.e. seroconversion rate)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>Diphtheria</condition>
  <condition>Pertussis</condition>
  <condition>Tetanus</condition>
  <condition>Hepatitis B</condition>
  <condition>Haemophilus Infections</condition>
  <arm_group>
    <arm_group_label>Quinvaxem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tritanrix Hib/HepB + Quinvaxem</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quinvaxem</intervention_name>
    <description>A single dose (0.5 mL) of Quinvaxem contains:
diphtheria antitoxin (&gt;= 30 IU), tetanus antitoxin (&gt;= 60 IU), whole-cell inactive pertussis bacteria (&gt;= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen
One dose of Quinvaxem given at Weeks 6, 10 and 14</description>
    <arm_group_label>Quinvaxem</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quinvaxem/Tritanrix</intervention_name>
    <description>A single dose (0.5 mL) of Quinvaxem contains:
diphtheria antitoxin (&gt;= 30 IU), tetanus antitoxin (&gt;= 60 IU), inactive pertussis bacteria (&gt;= 4 IU), 10 mcg Hib polysaccharide conjugate (approx. 25 mcg tetanus toxoid), 10 mcg Hepatitis B surface antigen
One dose of Quinvaxem given at Weeks 6, 10 and 14</description>
    <arm_group_label>Tritanrix Hib/HepB + Quinvaxem</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A male or female between, and including, 42 and 64 days of age at the time of the
             first vaccination

          -  Written informed consent obtained from parents/legal guardian of the subject

          -  Free of obvious health problems as established by medical history and/or clinical
             examination before entering the study

          -  Hepatitis B vaccination at birth (within 48 hours) Available for all scheduled study
             visits

        Exclusion Criteria:

          -  Use of any investigational drug or any investigational vaccine within 30 days
             preceding the first dose of study vaccine, or planned use during the study period and
             safety follow-up

          -  Planned administration of a vaccine not foreseen by the study protocol

          -  Known or suspected impairment of immune function, known Human immunodeficiency virus
             (HIV)-positivity, receiving immunosuppressive therapy, or having received systemic
             immunosuppressive therapy within 1 month prior to study entry (note: inhaled and
             topical steroids are allowed)

          -  Administration of parenteral immunoglobulin preparation and/or blood products since
             birth

          -  Previous vaccination against Haemophilus influenzae type b (Hib) and/or diphtheria,
             tetanus, pertussis (DTP)

          -  History of anaphylaxis, or any serious vaccine reaction, or allergy to any vaccine
             component or to products containing mercury compounds, such as sodium
             ethylmercuro-thiosalicylate

          -  Significant acute infection

          -  Any condition which, in the opinion of the investigator, might interfere with the
             evaluation of the study objectives

          -  Participation in another clinical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>42 Days</minimum_age>
    <maximum_age>64 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria RZ Capeding, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Institute for Tropical Medicine (RITM)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Institute for Tropical Medicine</name>
      <address>
        <city>Muntinlupa City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Philippines</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2011</study_first_submitted>
  <study_first_submitted_qc>May 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2011</study_first_posted>
  <results_first_submitted>March 27, 2013</results_first_submitted>
  <results_first_submitted_qc>March 27, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 22, 2013</results_first_posted>
  <last_update_submitted>August 29, 2013</last_update_submitted>
  <last_update_submitted_qc>August 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccination</keyword>
  <keyword>Immunisation</keyword>
  <keyword>Virus</keyword>
  <keyword>Diphtheria</keyword>
  <keyword>Pertussis</keyword>
  <keyword>Tetanus</keyword>
  <keyword>Hepatitis B</keyword>
  <keyword>Haemophilus Influenzae</keyword>
  <keyword>Immunity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Whooping Cough</mesh_term>
    <mesh_term>Tetanus</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Haemophilus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Tetanus Antitoxin</mesh_term>
    <mesh_term>Diphtheria Antitoxin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited at two vaccination sites in the Philippines:
First subject first visit (FSFV): 30 May 2011 Last subject last visit (LSLV): 30 September 2011</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Quinvaxem</title>
          <description>Three-dose schedule: 6, 10 and 14 weeks of age Weeks 6, 10 and 14: single doses of Quinvaxem</description>
        </group>
        <group group_id="P2">
          <title>Tritanrix Hib/HepB + Quinvaxem</title>
          <description>Three-dose schedule: 6, 10 and 14 weeks of age Week 6: single dose of Tritanrix HB+Hib Weeks 10 and 14: single doses of Quinvaxem</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
                <participants group_id="P2" count="200"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="198"/>
                <participants group_id="P2" count="195"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Quinvaxem</title>
          <description>Three-dose schedule: 6, 10 and 14 weeks of age Weeks 6, 10 and 14: single doses of Quinvaxem</description>
        </group>
        <group group_id="B2">
          <title>Tritanrix Hib/HepB + Quinvaxem</title>
          <description>Three-dose schedule: 6, 10 and 14 weeks of age Week 6: single dose of Tritanrix HB+Hib Weeks 10 and 14: single doses of Quinvaxem</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="200"/>
            <count group_id="B2" value="200"/>
            <count group_id="B3" value="400"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="200"/>
                    <measurement group_id="B2" value="200"/>
                    <measurement group_id="B3" value="400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.8" spread="0.91"/>
                    <measurement group_id="B2" value="6.7" spread="0.86"/>
                    <measurement group_id="B3" value="6.7" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Seroprotection Rate: Anti-PRP Antibodies</title>
        <description>Percentage of subjects with an anti-PRP titer ≥0.15 µg/mL (i.e. seroprotection rate)</description>
        <time_frame>1 month after the third vaccination</time_frame>
        <population>Available observations at Visit 4</population>
        <group_list>
          <group group_id="O1">
            <title>Quinvaxem</title>
            <description>Three-dose schedule: 6, 10 and 14 weeks of age Weeks 6, 10 and 14: single doses of Quinvaxem</description>
          </group>
          <group group_id="O2">
            <title>Tritanrix Hib/HepB + Quinvaxem</title>
            <description>Three-dose schedule: 6, 10 and 14 weeks of age Week 6: single dose of Tritanrix HB+Hib Weeks 10 and 14: single doses of Quinvaxem</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Rate: Anti-PRP Antibodies</title>
          <description>Percentage of subjects with an anti-PRP titer ≥0.15 µg/mL (i.e. seroprotection rate)</description>
          <population>Available observations at Visit 4</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98.1" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="98.1" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroprotection Rate: Anti-hepatitis B Surface Antibodies</title>
        <description>Percentage of subjects with an anti-hepatitis B surface antibody titer ≥10 IU/L (i.e. seroprotection rate)</description>
        <time_frame>1 month after the third vaccination</time_frame>
        <population>Available observations at Visit 4</population>
        <group_list>
          <group group_id="O1">
            <title>Quinvaxem</title>
            <description>Three-dose schedule: 6, 10 and 14 weeks of age Weeks 6, 10 and 14: single doses of Quinvaxem</description>
          </group>
          <group group_id="O2">
            <title>Tritanrix Hib/HepB + Quinvaxem</title>
            <description>Three-dose schedule: 6, 10 and 14 weeks of age Week 6: single dose of Tritanrix HB+Hib Weeks 10 and 14: single doses of Quinvaxem</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Rate: Anti-hepatitis B Surface Antibodies</title>
          <description>Percentage of subjects with an anti-hepatitis B surface antibody titer ≥10 IU/L (i.e. seroprotection rate)</description>
          <population>Available observations at Visit 4</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.9" lower_limit="90.9" upper_limit="97.6"/>
                    <measurement group_id="O2" value="97.4" lower_limit="94.1" upper_limit="99.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroprotection Rate: Anti-diphtheria Toxoid Antibodies</title>
        <description>Percentage of subjects with antibody levels against diphtheria toxoid ≥0.1 IU/mL (i.e. seroprotection rate)</description>
        <time_frame>1 month after the third vaccination</time_frame>
        <population>Available observations at Visit 4</population>
        <group_list>
          <group group_id="O1">
            <title>Quinvaxem</title>
            <description>Three-dose schedule: 6, 10 and 14 weeks of age Weeks 6, 10 and 14: single doses of Quinvaxem</description>
          </group>
          <group group_id="O2">
            <title>Tritanrix Hib/HepB + Quinvaxem</title>
            <description>Three-dose schedule: 6, 10 and 14 weeks of age Week 6: single dose of Tritanrix HB+Hib Weeks 10 and 14: single doses of Quinvaxem</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Rate: Anti-diphtheria Toxoid Antibodies</title>
          <description>Percentage of subjects with antibody levels against diphtheria toxoid ≥0.1 IU/mL (i.e. seroprotection rate)</description>
          <population>Available observations at Visit 4</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.5" lower_limit="97.2" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="98.1" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroprotection Rate: Anti-tetanus Toxoid Antibodies</title>
        <description>Percentage of subjects with antibody levels against tetanus toxoid ≥0.1 IU/mL (i.e. seroprotection rate)</description>
        <time_frame>1 month after the third vaccination</time_frame>
        <population>Available observations at Visit 4</population>
        <group_list>
          <group group_id="O1">
            <title>Quinvaxem</title>
            <description>Three-dose schedule: 6, 10 and 14 weeks of age Weeks 6, 10 and 14: single doses of Quinvaxem</description>
          </group>
          <group group_id="O2">
            <title>Tritanrix Hib/HepB + Quinvaxem</title>
            <description>Three-dose schedule: 6, 10 and 14 weeks of age Week 6: single dose of Tritanrix HB+Hib Weeks 10 and 14: single doses of Quinvaxem</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Rate: Anti-tetanus Toxoid Antibodies</title>
          <description>Percentage of subjects with antibody levels against tetanus toxoid ≥0.1 IU/mL (i.e. seroprotection rate)</description>
          <population>Available observations at Visit 4</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98.2" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="98.1" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroprotection Rate: Anti-B. Pertussis Antibodies</title>
        <description>Percentage of subjects with an anti-B. pertussis antibody titer ≥20 EU/mL or a 4-fold increase over baseline (i.e. seroconversion rate)</description>
        <time_frame>1 month after the third vaccination</time_frame>
        <population>Available observations at Visit 4</population>
        <group_list>
          <group group_id="O1">
            <title>Quinvaxem</title>
            <description>Three-dose schedule: 6, 10 and 14 weeks of age Weeks 6, 10 and 14: single doses of Quinvaxem</description>
          </group>
          <group group_id="O2">
            <title>Tritanrix Hib/HepB + Quinvaxem</title>
            <description>Three-dose schedule: 6, 10 and 14 weeks of age Week 6: single dose of Tritanrix HB+Hib Weeks 10 and 14: single doses of Quinvaxem</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Rate: Anti-B. Pertussis Antibodies</title>
          <description>Percentage of subjects with an anti-B. pertussis antibody titer ≥20 EU/mL or a 4-fold increase over baseline (i.e. seroconversion rate)</description>
          <population>Available observations at Visit 4</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.0" lower_limit="96.4" upper_limit="99.9"/>
                    <measurement group_id="O2" value="100" lower_limit="98.1" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited local and systemic AEs were collected on the day of vaccination, and for the four days after the day of each vaccination. Unsolicited AEs were collected at each study visit up to Day 85.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Quinvaxem</title>
          <description>Three-dose schedule: 6, 10 and 14 weeks of age Weeks 6, 10 and 14: single doses of Quinvaxem</description>
        </group>
        <group group_id="E2">
          <title>Tritanrix Hib/HepB + Quinvaxem</title>
          <description>Three-dose schedule: 6, 10 and 14 weeks of age Week 6: single dose of Tritanrix HB+Hib Weeks 10 and 14: single doses of Quinvaxem</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Idiopathic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral encephalitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="180" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="180" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="293" subjects_affected="137" subjects_at_risk="200"/>
                <counts group_id="E2" events="338" subjects_affected="157" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="138" subjects_affected="74" subjects_at_risk="200"/>
                <counts group_id="E2" events="145" subjects_affected="82" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="87" subjects_affected="59" subjects_at_risk="200"/>
                <counts group_id="E2" events="73" subjects_affected="54" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="133" subjects_affected="88" subjects_at_risk="200"/>
                <counts group_id="E2" events="137" subjects_affected="95" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="55" subjects_affected="46" subjects_at_risk="200"/>
                <counts group_id="E2" events="69" subjects_affected="54" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="200"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="200"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="200"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any material for public dissemination will be submitted to the Sponsor for review at least ninety (90) days prior to submission for publication, public dissemination, or review by a publication committee</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Affairs Director</name_or_title>
      <organization>Crucell Switzerland AG</organization>
      <phone>+41(0)319086111</phone>
      <email>info@crucell.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

